AML1/MTG16 fusion gene from a t(16;21)(q24;q22) translocation in treatment-induced leukemia after breast cancer.
R
R
La Starza
C
C
Sambani
B
B
Crescenzi
C
C
Matteucci
M F
MF
Martelli
C
C
Mecucci
D000208:Acute Disease; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000633:toxicity; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology*; D002885:Chromosomes, Human, Pair 16; D002891:Chromosomes, Human, Pair 21; D050676:Core Binding Factor Alpha 2 Subunit; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000139:chemically induced*; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000139:chemically induced*; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D014157:Transcription Factors / Q000235:genetics*; D014178:Translocation, Genetic
C112643:AML1-MTG16 protein, human; D050676:Core Binding Factor Alpha 2 Subunit; D015514:Oncogene Proteins, Fusion; D014157:Transcription Factors